At ASCO 2025, Bayer announced new data from recent clinical trials that highlight significant advancements in both prostate ...

Novo Nordisk has reduced the price of its two semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – to ...

Skyhawk recently started dosing patients in its phase 2/3 FALCON-HD trial of lead candidate SKY-0515, involving patients with ...

Tonmya – a new under-the-tongue formulation of well-established muscle relaxant cyclobenzaprine HCl – has been cleared to ...

The convergence of behavioural health and movement disorder assessment technologies represents just the beginning of a ...

Along with plenty of initiatives in areas like food and exposure to chemicals like pesticides, the document (PDF), acquired ...

Novo Nordisk's GLP-1 drugs have been under considerable competitive pressure in the last few months, so the company will be ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

Precigen has won approval in the US for a first-in-class immunotherapy for recurrent respiratory papillomatosis (RRP), a rare ...

Insmed has claimed the distinction of becoming the first company to get FDA approval for a treatment for chronic lung disease ...

Confirmation of that has come in the form of an update (PDF) from the New Jersey Department of Labour and Workforce ...

The deal – which has a total value of up to $1.3 billion including an unspecified upfront payment – gives Bayer exclusive ...